Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 1 (2004), Issue 3 (October)

1. TCDD and PCBs inhibit breast cancer cell proliferation in vitro.
   Toxicol In Vitro, 18(6): 811-9. [Abstract] [Full-text]
2. Glycoprotein isolated from Solanum nigrum L. inhibits the DNA-binding activities of NF-kappaB and AP-1, and increases the production of nitric oxide in TPA-stimulated MCF-7 cells.
   Toxicol In Vitro, 18(6): 755-63. [Abstract] [Full-text]
3. Changes in temporal patterns of local failure after breast-conserving therapy and their prognostic implications.
   Int J Radiat Oncol Biol Phys, 60(3): 731-40. [Abstract] [Full-text]
4. Defining the clinical target volume for patients with early-stage breast cancer treated with lumpectomy and accelerated partial breast irradiation: a pathologic analysis.
   Int J Radiat Oncol Biol Phys, 60(3): 722-30. [Abstract] [Full-text]
5. Incidence of internal mammary node metastases after a sentinel lymph node technique in breast cancer and its implication in the radiotherapy plan.
   Int J Radiat Oncol Biol Phys, 60(3): 715-21. [Abstract] [Full-text]
6. Results of a survey regarding irradiation of internal mammary chain in patients with breast cancer: practice is culture driven rather than evidence based.
   Int J Radiat Oncol Biol Phys, 60(3): 706-14. [Abstract] [Full-text]
7. Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation.
   Mol Carcinog, 41(3): 164-78. [Abstract] [Full-text]
8. Adenosine stimulation of proliferation of breast carcinoma cell lines: evaluation of the [3H]thymidine assay system and modulatory effects of the cellular microenvironment in vitro.
   J Cell Physiol, 201(3): 429-38. [Abstract] [Full-text]
9. Ethanol-induced in vitro invasion of breast cancer cells: the contribution of MMP-2 by fibroblasts.
   Int J Cancer, 112(5): 738-46. [Abstract] [Full-text]
10. Aberrant alternative exon use and increased copy number of human metalloprotease-disintegrin ADAM15 gene in breast cancer cells.
    Genes Chromosomes Cancer, 41(4): 366-78. [Abstract] [Full-text]
11. Bone resorption activity of osteolytic metastatic lung and breast cancers.
    J Orthop Res, 22(6): 1161-7. [Abstract] [Full-text]
12. BAG-1: a multi-functional pro-survival molecule.
    Int J Biochem Cell Biol, 37(2): 251-9. [Abstract] [Full-text]
13. Over-expression of the p110beta but not p110alpha isoform of PI 3-kinase inhibits motility in breast cancer cells.
    Cell Motil Cytoskeleton, 59(3): 180-8. [Abstract] [Full-text]
14. The significance of the diagnosis of atypia in breast fine-needle aspiration.
    Diagn Cytopathol, 31(5): 285-8. [Abstract] [Full-text]
15. Nonepithelial malignancies mimicking primary carcinoma of the breast.
    Diagn Cytopathol, 31(5): 352-7. [Abstract] [Full-text]
16. Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer.
    Gene Ther, 11(21): 1579-89. [Abstract] [Full-text]
17. Diffusion of breast conserving surgery in medical communities.
    Soc Sci Med, 60(1): 143-51. [Abstract] [Full-text]
18. Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients.
    J Oral Pathol Med, 33(10): 589-94. [Abstract] [Full-text]
19. Analysis of familial male breast cancer for germline mutations in CHEK2.
    Cancer Lett, 215(2): 187-9. [Abstract] [Full-text]
20. Fluorodeoxyglucose-PET in the management of breast cancer.
    Radiol Clin North Am, 42(6): 1113-22, ix. [Abstract] [Full-text]
21. Breast cancer risk during HRT: influence of estradiol metabolites on breast cancer and endothelial cell proliferation.
    Maturitas, 49(3): 235-40. [Abstract] [Full-text]
22. Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations.
    Eur J Hum Genet, 12(11): 899-906. [Abstract] [Full-text]
23. Primary chemotherapy with doxorubicin and paclitaxel in patients with early breast cancer: final results of a multicenter phase II study.
    J Cancer Res Clin Oncol, 130(11): 657-63. [Abstract] [Full-text]
24. Refined morphologic criteria for tubular carcinoma to retain its favorable outcome status in contemporary breast carcinoma patients.
    Am J Clin Pathol, 122(5): 728-39. [Abstract] [Full-text]
25. Hypercholesterolemia impairs angiogenesis in patients with breast carcinoma and, therefore, lowers the risk of metastases.
    Am J Clin Pathol, 122(5): 696-703. [Abstract] [Full-text]
26. Unexpected metastatic lobular carcinoma of the breast with intraabdominal spread and subsequent port-site metastasis after diagnostic laparoscopy for exclusion of ovarian cancer.
    Gynecol Oncol, 95(2): 405-8. [Abstract] [Full-text]
27. Absence of association with cancer risk and low frequency of alterations at a p53 responsive PIG3 gene polymorphism in breast and lung carcinomas.
    Mutat Res, 556(1): 143-50. [Abstract] [Full-text]
28. Detection of human papillomavirus DNA in breast cancer of patients with cervical cancer history.
    J Clin Virol, 31(4): 292-7. [Abstract] [Full-text]
29. Estrogen receptor-associated expression of keratinocyte growth factor and its possible role in the inhibition of apoptosis in human breast cancer.
    Lab Invest, 84(11): 1460-71. [Abstract] [Full-text]
30. Influence of slide aging on results of translational research studies using immunohistochemistry.
    Mod Pathol, 17(11): 1414-20. [Abstract] [Full-text]
31. Risk factors for breast cancer in elderly women.
    Am J Epidemiol, 160(9): 868-75. [Abstract] [Full-text]
32. CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review.
    Am J Epidemiol, 160(9): 825-41. [Abstract] [Full-text]
33. Breast cancer mortality patterns and time trends in 10 new EU member states: mortality declining in young women, but still increasing in the elderly.
    Int J Cancer, 112(6): 1056-64. [Abstract] [Full-text]
34. Breast cancer bone metastasis in femur: surgical considerations and reconstruction with Long Gamma Nail.
    Eur J Surg Oncol, 30(9): 993-7. [Abstract] [Full-text]
35. Stewart-Treves syndrome--treatment and outcome in six patients from a single centre.
    Eur J Surg Oncol, 30(9): 982-6. [Abstract] [Full-text]
36. Surgical implications of sentinel node with micrometastatic disease in invasive breast cancer.
    Eur J Surg Oncol, 30(9): 924-9. [Abstract] [Full-text]
37. Radioguided occult lesion localisation (ROLL) and sentinel node biopsy for impalpable invasive breast cancer.
    Eur J Surg Oncol, 30(9): 918-23. [Abstract] [Full-text]
38. Blue dye versus combined blue dye-radioactive tracer technique in detection of sentinel lymph node in breast cancer.
    Eur J Surg Oncol, 30(9): 913-7. [Abstract] [Full-text]
39. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.
    Blood, 104(9): 2940-2. [Abstract] [Full-text]
40. Sulforaphane halts breast cancer cell growth.
    Drug Discov Today, 9(21): 908. [Abstract] [Full-text]
41. Ligand-independent and agonist-mediated degradation of estrogen receptor-alpha in breast carcinoma cells: evidence for distinct degradative pathways.
    Mol Cell Endocrinol, 227(1): 53-65. [Abstract] [Full-text]
42. How do we manage breast cancer in the elderly patients? A survey among members of the British Association of Surgical Oncologists (BASO).
    Crit Rev Oncol Hematol, 52(2): 135-41. [Abstract] [Full-text]
43. Mutational spectrum of p53 mutations in primary breast and ovarian tumors.
    Crit Rev Oncol Hematol, 52(2): 103-16. [Abstract] [Full-text]
44. Prognostic significance of intra-tumoral estradiol level in breast cancer patients.
    Cancer Lett, 216(1): 115-21. [Abstract] [Full-text]
45. Tankyrase, a positive regulator of telomere elongation, is over expressed in human breast cancer.
    Cancer Lett, 216(1): 81-7. [Abstract] [Full-text]
46. RNA expression of human telomerase subunits TR and TERT is differentially affected by melatonin receptor agonists in the MCF-7 tumor cell line.
    Cancer Lett, 216(1): 73-80. [Abstract] [Full-text]
47. Mammaglobin as a novel breast cancer biomarker: multigene reverse transcription-PCR assay and sandwich ELISA.
    Clin Chem, 50(11): 2069-76. [Abstract] [Full-text]
48. Survivin is an independent prognostic marker for risk stratification of breast cancer patients.
    Clin Chem, 50(11): 1986-93. [Abstract] [Full-text]
49. The relationship between vascular and metabolic characteristics of primary breast tumours.
    Eur Radiol, 14(11): 2038-45. [Abstract] [Full-text]
50. MRI after magnetic drug targeting in patients with advanced solid malignant tumors.
    Eur Radiol, 14(11): 1949-55. [Abstract] [Full-text]
51. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.
    Biol Blood Marrow Transplant, 10(11): 794-804. [Abstract] [Full-text]
52. Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis.
    J Cell Biol, 167(2): 215-21. [Abstract] [Full-text]
53. Dendritic cells fused with human cancer cells: morphology, antigen expression, and T cell stimulation.
    Clin Immunol, 113(3): 261-9. [Abstract] [Full-text]
54. The management of ductal carcinoma in situ in North America and Europe. Results of a survey.
    Cancer, 101(9): 1958-67. [Abstract] [Full-text]
55. Contralateral prophylactic mastectomy. Predictors of significant histologic findings.
    Cancer, 101(9): 1977-86. [Abstract] [Full-text]
56. Mitogenic activity of estrogens in human breast cancer cells does not rely on direct induction of mitogen-activated protein kinase/extracellularly regulated kinase or phosphatidylinositol 3-kinase.
    Mol Endocrinol, 18(11): 2700-13. [Abstract] [Full-text]
57. Miniature tissue microarrays for HercepTest standardisation and analysis.
    J Clin Pathol, 57(11): 1229-31. [Abstract] [Full-text]
58. WHO reclassification of breast lymphomas.
    J Clin Pathol, 57(11): 1213-4. [Abstract] [Full-text]
59. Expression of ATM, p53, and the MRE11-Rad50-NBS1 complex in myoepithelial cells from benign and malignant proliferations of the breast.
    J Clin Pathol, 57(11): 1179-84. [Abstract] [Full-text]
60. Use of tissue microarray for interlaboratory validation of HER2 immunocytochemical and FISH testing.
    J Clin Pathol, 57(11): 1140-4. [Abstract] [Full-text]
61. Belief importance and the theory of planned behaviour: comparing modal and ranked modal beliefs in predicting attendance at breast screening.
    Br J Health Psychol, 9: 447-63. [Abstract] [Full-text]
62. AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity.
    Oncogene, 23(50): 8238-46. [Abstract] [Full-text]
63. Expression of the NF-kappaB-responsive gene BTG2 is aberrantly regulated in breast cancer.
    Oncogene, 23(50): 8310-9. [Abstract] [Full-text]
64. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.
    J Clin Oncol, 22(21): 4261-71. [Abstract] [Full-text]
65. MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer.
    J Magn Reson Imaging, 20(5): 865-73. [Abstract] [Full-text]
66. Microdissection and SAGE as a combined tool to reveal gene expression in ductal carcinoma in situ of the breast.
    Mol Carcinog, 41(4): 197-206. [Abstract] [Full-text]
67. Comparison of cancer survival in UK and Australia: rates are higher in Australia for three major sites.
    Br J Cancer, 91(9): 1663-5. [Abstract] [Full-text]
68. Inverse relationship between ER-beta and SRC-1 predicts outcome in endocrine-resistant breast cancer.
    Br J Cancer, 91(9): 1687-93. [Abstract] [Full-text]
69. Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells.
    Br J Cancer, 91(9): 1703-10. [Abstract] [Full-text]
70. Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers.
    Br J Cancer, 91(9): 1694-702. [Abstract] [Full-text]
71. Birth weight is associated with postmenopausal breast cancer risk in Swedish women.
    Br J Cancer, 91(9): 1666-8. [Abstract] [Full-text]
72. FISH cytogenetics and prognosis in breast and non-small cell lung cancers.
    Cytometry B Clin Cytom, 62(1): 52-6. [Abstract] [Full-text]
73. Effect of cognitive-existential group therapy on survival in early-stage breast cancer.
    J Clin Oncol, 22(21): 4255-60. [Abstract] [Full-text]
74. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.
    J Clin Oncol, 22(21): 4247-54. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.